In addition, it did not reduce cardiovascular death or heart failure hospitalizations in patients with high N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (≥ 8000 pg/ml) in VICTORIA (A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction) whereas omecamtiv mecarbil was associated with better outcomes in patients with more severe cardiac dysfunction, as shown by a left ventricular ejection fraction (LVEF) of 28% or less (median values).39,40. The gene discussed is NPPB; the disease is heart failure.